Rezūm™
Water Vapor Therapy

Transform the BPH treatment experience for your patients with a durable, minimally invasive, office-based alternative to medical management

- First-line therapy option¹
- Low retreatment rate²
- Preserves sexual function³
- Doesn’t require a permanent implant
- Able to treat prostates with hyperplasia of the lateral lobes, central zone and/or median lobe
- Included in 2018 AUA guidelines, dedicated CPT© code⁴

How does the Rezūm System work?
The Rezūm System is a transurethral thermal therapy that uses sterile water vapor (steam) to treat BPH by delivering targeted, controlled doses of thermal energy directly to the prostate gland, targeting and reducing the obstructive tissue that causes BPH.

CPT Copyright 2018 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.
Study results show that Rezūm™ Water Vapor Therapy demonstrates durability and significant, sustained BPH symptom relief through 4 years.

Rezūm Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: 4-Year Results from Randomized Controlled Study

In Press: Urology, January 2019 | Authors: McVary KT, Rogers T, Roehrborn CG

The latest published analysis offers evidence that Rezūm Water Vapor Therapy demonstrates significant, sustained improvement of lower urinary tract symptoms (LUTS) and QOL for patients treated for benign prostatic hyperplasia (BPH) through 4 years post-procedure. Improvements as measured by IPSS, QOL, Qmax and BPHII show durability with consistent improvement from initial reporting at 3 months.

4-Year Study Data by the Numbers

<table>
<thead>
<tr>
<th>135 Subjects</th>
<th>15 Sites</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Surgical Retreatment Rate</strong></td>
<td>4.4%</td>
</tr>
<tr>
<td><strong>International Prostate Symptom Score (IPSS)</strong></td>
<td><strong>10.1 pts</strong> (46.7%)</td>
</tr>
<tr>
<td><strong>Quality of Life Impact (QOL)</strong></td>
<td><strong>2.0 pts</strong> (42.9%)</td>
</tr>
<tr>
<td><strong>Maximum Flow Rate (Qmax)</strong></td>
<td><strong>4.2 mL/sec</strong> (49.5%)</td>
</tr>
<tr>
<td><strong>BPH Impact Index (BPHII)</strong></td>
<td><strong>3.5 pts</strong> (52.2%)</td>
</tr>
</tbody>
</table>

In addition to symptom and QOL improvements, surgical retreatment was low, with surgical intervention performed on just 4.4% of subjects through 4 years. Study results show a positive safety profile with preservation of sexual function, and no late-occurring related adverse events or de novo erectile dysfunction reported at 4 years.

To learn more about Rezūm Water Vapor Therapy or our portfolio of BPH treatment options, contact your Boston Scientific representative or visit bostonscientific.com/bph